Monopar Therapeutics (NASDAQ:MNPR) Upgraded to "Strong-Buy" at Jones Trading

Key Points

• Monopar Therapeutics was upgraded to a "Strong-Buy" rating by Jones Trading, reflecting a positive shift in investor sentiment.
• Several analysts have set a range of target prices for the stock, with a consensus target price of $103.25, while two analysts rated the stock as a Strong Buy.
• Insider trading activity has been notable, with significant share sales by executives, indicating potential shifts in ownership stakes within the company.

Monopar Therapeutics (NASDAQ:MNPR - Get Free Report) was upgraded by research analysts at Jones Trading from a "hold" rating to a "strong-buy" rating in a research note issued on Friday,Zacks.com reports.

Several other equities analysts also recently weighed in on MNPR. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Monopar Therapeutics in a research report on Wednesday. HC Wainwright set a $105.00 target price on Monopar Therapeutics and gave the company a "buy" rating in a research report on Monday, September 29th. Piper Sandler set a $95.00 target price on Monopar Therapeutics and gave the company an "overweight" rating in a research report on Thursday, September 25th. Lake Street Capital assumed coverage on Monopar Therapeutics in a research report on Tuesday, September 23rd. They issued a "buy" rating and a $106.00 target price for the company. Finally, BTIG Research boosted their price objective on Monopar Therapeutics from $87.00 to $104.00 and gave the stock a "buy" rating in a research report on Thursday, September 25th. Two equities research analysts have rated the stock with a Strong Buy rating, seven have assigned a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Buy" and a consensus target price of $103.25.

Monopar Therapeutics Price Performance

NASDAQ MNPR opened at $87.82 on Friday. The company has a market cap of $541.85 million, a P/E ratio of -26.37 and a beta of 1.42. The stock has a 50-day moving average of $54.12 and a two-hundred day moving average of $43.28. Monopar Therapeutics has a 1-year low of $4.50 and a 1-year high of $105.00.

Monopar Therapeutics (NASDAQ:MNPR - Get Free Report) last released its earnings results on Tuesday, August 12th. The company reported ($0.35) earnings per share for the quarter, beating the consensus estimate of ($0.47) by $0.12. On average, analysts anticipate that Monopar Therapeutics will post -1.65 EPS for the current fiscal year.

Insiders Place Their Bets

In related news, Director Christopher M. Starr sold 16,800 shares of the company's stock in a transaction that occurred on Monday, July 14th. The stock was sold at an average price of $40.00, for a total value of $672,000.00. Following the completion of the transaction, the director directly owned 5,173 shares of the company's stock, valued at $206,920. This represents a 76.46% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CEO Chandler Robinson sold 16,800 shares of the company's stock in a transaction that occurred on Monday, July 14th. The shares were sold at an average price of $40.00, for a total value of $672,000.00. Following the completion of the transaction, the chief executive officer directly owned 73,472 shares of the company's stock, valued at $2,938,880. This trade represents a 18.61% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 592,733 shares of company stock valued at $36,700,227. 20.50% of the stock is owned by company insiders.

Hedge Funds Weigh In On Monopar Therapeutics

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Police & Firemen s Retirement System of New Jersey acquired a new position in Monopar Therapeutics in the second quarter valued at approximately $34,000. AlphaQuest LLC acquired a new position in Monopar Therapeutics in the first quarter valued at approximately $44,000. JPMorgan Chase & Co. boosted its holdings in Monopar Therapeutics by 1,821.0% in the second quarter. JPMorgan Chase & Co. now owns 1,921 shares of the company's stock valued at $69,000 after purchasing an additional 1,821 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. acquired a new position in Monopar Therapeutics in the second quarter valued at approximately $80,000. Finally, New York State Common Retirement Fund acquired a new position in Monopar Therapeutics in the second quarter valued at approximately $104,000. 1.83% of the stock is owned by institutional investors and hedge funds.

About Monopar Therapeutics

Monopar Therapeutics Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe oral mucositis in patients with oropharyngeal cancer.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.